The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, B.-C.
Right arrow Articles by Lin, C.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, B.-C.
Right arrow Articles by Lin, C.-H.
The Journal of Immunology, 2006, 177: 681-693.
Copyright © 2006 by The American Association of Immunologists

Peptidoglycan-Induced IL-6 Production in RAW 264.7 Macrophages Is Mediated by Cyclooxygenase-2, PGE2/PGE4 Receptors, Protein Kinase A, I{kappa}B Kinase, and NF-{kappa}B1

Bing-Chang Chen*, Chiao-Chun Liao{dagger}, Ming-Jen Hsu{ddagger}, Yi-Ting Liao{ddagger}, Chia-Chin Lin§, Joen-Rong Sheu{ddagger} and Chien-Huang Lin2,{ddagger}

* School of Respiratory Therapy, Graduate Institutes of {dagger} Biomedical Technology and {ddagger} Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan; and § Graduate Institute of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
In this study, we investigated the signaling pathway involved in IL-6 production caused by peptidoglycan (PGN), a cell wall component of the Gram-positive bacterium, Staphylococcus aureus, in RAW 264.7 macrophages. PGN caused concentration- and time-dependent increases in IL-6, PGE2, and cAMP production. PGN-mediated IL-6 production was inhibited by a nonselective cyclooxygenase (COX) inhibitor (indomethacin), a selective COX-2 inhibitor (NS398), a PGE2 (EP2) antagonist (AH6809), a PGE4 (EP4) antagonist (AH23848), and a protein kinase A (PKA) inhibitor (KT5720), but not by a nonselective NO synthase inhibitor (NG-nitro-L-arginine methyl ester). Furthermore, PGE2, an EP2 agonist (butaprost), an EP2/PGE3 (EP3)/EP4 agonist (misoprostol), and misoprostol in the presence of AH6809 all induced IL-6 production, whereas an EP1/EP3 agonist (sulprostone) did not. PGN caused time-dependent activations of I{kappa}B kinase {alpha}beta (IKKdbeta) and p65 phosphorylation at Ser276, and these effects were inhibited by NS398 and KT5720. Both PGE2 and 8-bromo-cAMP also caused IKKdbeta kinase {alpha}beta phosphorylation. PGN resulted in two waves of the formation of NF-{kappa}B-specific DNA-protein complexes. The first wave of NF-{kappa}B activation occurred at 10–60 min of treatment, whereas the later wave occurred at 2–12 h of treatment. The PGN-induced increase in {kappa}B luciferase activity was inhibited by NS398, AH6809, AH23848, KT5720, a protein kinase C inhibitor (Ro31-8220), and a p38 MAPK inhibitor (SB203580). These results suggest that PGN-induced IL-6 production involves COX-2-generated PGE2, activation of the EP2 and EP4 receptors, cAMP formation, and the activation of PKA, protein kinase C, p38 MAPK, IKKdbeta, kinase {alpha}beta, p65 phosphorylation, and NF-{kappa}B. However, PGN-induced NO release is not involved in the signaling pathway of PGN-induced IL-6 production.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Bacteria stimulate the innate immune system of a host and the release of inflammatory molecules such as cytokines and chemokines as a response to infections (1, 2). LPS is a well-known activator of the innate immune system in Gram-negative infections (3). During Gram-positive infections, when no endotoxin is present, peptidoglycan (PGN),3 the major component of the cell wall of Gram-positive bacteria, activates the innate immune system of the host and induces the release of cytokines (TNF-{alpha}, IL-1, and IL-6) and chemokines (IL-8/CXCL8, MIP-1, MIP-2, and MCP) (3, 4, 5). These inflammatory molecules are the major cause of the various signs and symptoms that occur during bacterial infections, including fever, inflammation, and acute phase responses (3, 4, 5).

IL-6 is a multifunctional cytokine that plays a central role in both innate and acquired immune responses. IL-6 is the predominant mediator of the acute phase response, an innate immune mechanism which is triggered by infection and inflammation (6, 7). IL-6 also plays multiple roles during the subsequent development of acquired immunity against incoming pathogens, including regulation of the expressions of cytokine and chemokine, stimulation of Ab production by B cells, regulation of macrophage and dendritic cell differentiation, and the response of regulatory T cells to microbial infection (6, 7). In addition to these roles in pathogen-specific inflammation and immunity, IL-6 levels are elevated in chronic inflammatory conditions, such as rheumatoid arthritis (8, 9, 10). Several consensus sequences, including those for NF-{kappa}B, CREB, NF-IL-6, and AP-1 in the 5' promoter region of the IL-6 gene, have been identified as regulatory sequences that induce IL-6 in response to various stimuli (11, 12). NF-{kappa}B, a key transcription factor that regulates IL-6 expression, is a dimer of either transcription factor p65 or transcription factor p50 (13). In a resting state, this dimer is associated with I{kappa}Bs to retain NF-{kappa}B in the cytosol (14). I{kappa}B kinase (IKK), which is activated through stimulation by cytokines and bacterial products, phosphorylates I{kappa}B{alpha} at Ser32 and Ser36 and I{kappa}Bbeta at Ser19 and Ser23 (15, 16, 17), to produce ubiquitination of I{kappa}B{alpha}beta at lysine residues and degradation by the 26S proteasome (18). This process releases active NF-{kappa}B, which is then translocated from the cytosol to the nucleus, to bind specific DNA enhancer sequences and induce gene transcription (13). Regulation of I{kappa}B degradation and the subsequent release of NF-{kappa}B constitute a critical control point in the pathway. However, recent results suggest that an additional I{kappa}B-independent pathway is activated, which causes the enhanced transactivation potential of NF-{kappa}B once it is bound to its consensus sequence (19, 20). Activation of the pathway has been shown to result in increased phosphorylation of the p65 (RelA) subunit of NF-{kappa}B and to promote interaction of p65 with the coactivator protein, p300/CBP (21, 22, 23).

PGs are ubiquitous compounds involved in a variety of homeostatic and inflammatory processes (24). They are formed by the combined action of phospholipase A2, which liberates arachidonic acid from the sn-2 position of cellular membrane phospholipids, and cyclooxygenase (COX), which converts arachidonic acid to the endoperoxide intermediate, PGH2. PGH2 is then subsequently converted to various PGs by the action of cell-specific synthases (24). COX-2 is a COX isoform that is induced in a number of cells by proinflammatory stimuli and is thought to contribute to the generation of prostanoids at sites of inflammation (25, 26). It is considered to be responsible for the high production of PGs (27). PGE2, one of the major PGs produced, exerts its biological effects by binding to specific cell surface receptors, designated PGE2 receptors (EPs). There are four different EPs that have been identified, named EP1 to EP4, and several splice variants of EP3 are known (28). Activation of EPs leads to well-defined alterations in intracellular calcium and cAMP concentrations; e.g., Gs-coupled cAMP increases via adenylyl cyclase activation by EP2 and EP4, and intracellular calcium increases via phosphatidylinositol turnover by EP1, whereas a Gi-coupled decrease in cAMP is effected by EP3 (29). Therefore, many different physiological processes are regulated by PGE2 activation of specific receptor subtypes.

Previous studies have shown a positive association between endogenous PGE2 production and IL-6 synthesis both in vitro (30, 31, 32, 33) and in vivo (31, 34). However, the signaling pathway between COX-2 induction and IL-6 release by PGN stimulation is still unknown. A recent study from our laboratory showed that PGN induces TLR2, p85{alpha}, and Ras complex formation and subsequently activates the Ras/Raf-1/ERK pathway, which in turn initiates IKK{alpha}beta and NF-{kappa}B activation, and ultimately induces COX-2 expression in RAW 264.7 macrophages (35). In the present study, RAW 264.7 macrophages were exposed to PGN, and the signaling pathway between COX-2 induction and IL-6 production was investigated. Our studies demonstrated that in RAW 264.7 macrophages, PGN stimulates IL-6 production by a COX-2/PGE2-dependent mechanism. We show that EP2/EP4, intracellular cAMP formation, and the activation of PKA, protein kinase C (PKC), p38 MAPK, IKK{alpha}beta, p65 phosphorylation, and NF-{kappa}B are involved in PGN-stimulated IL-6 production. However, PGN-induced NO release is not involved in the signaling pathway of PGN-induced IL-6 production.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Materials

PGN (derived from Staphylococcus aureus) was purchased from Fluka. LPS (derived from Escherichia coli), NG-nitro-L-arginine methyl ester (L-NAME), polymyxin B, AH23848, and misoprostol were purchased from Sigma-Aldrich. NS398, KT5720, Ro31-8220, SB203580, and 8-bromo-cAMP were obtained from Calbiochem. PGE2, AH6809, butaprost, sulprostone, and the IL-6, PGE2, and cAMP enzyme immunoassay kits were obtained from Cayman. DMEM/Ham’s F-12, FCS, and penicillin/streptomycin were purchased from Invitrogen Life Technologies. Abs specific for COX-2 and {alpha}-tubulin were purchased from Transduction Laboratories. Protein A/G beads, I{kappa}B{alpha} protein (aa 1–317), and Abs specific for IKK{alpha}beta phosphorylated at Ser180/181 and p65 phosphorylated at Ser276 were purchased from Cell Signaling and Neuroscience. IKK{alpha}beta, p65, p50, inducible NO synthase (iNOS), and anti-mouse and anti-rabbit IgG-conjugated HRP were purchased from Santa Cruz Biotechnology. Anti-mouse and anti-rabbit IgG-conjugated alkaline phosphatases were purchased from Jackson ImmunoResearch Laboratories. pGL2-ELAM-Luc (which is under the control of one NF-{kappa}B binding site) and pBK-CMV-LacZ were kindly provided by Dr. W.-W. Lin (National Taiwan University, Taipei, Taiwan). [{gamma}-32P]ATP (6000 Ci/mmol) was purchased from Amersham Pharmacia Biotech. IL-6 was purchased from PeproTech. Anti-IL-6 Ab was purchased from eBioscience. GenePOPTER 2 was purchased from Gene Therapy System. All materials for SDS-PAGE were purchased from Bio-Rad. All other chemicals were obtained from Sigma-Aldrich.

Cell culture

The mouse macrophage cell line, RAW 264.7, was obtained from American Type Culture Collection, and cells were maintained in DMEM/Ham’s F-12 nutrient mixture containing 10% FCS, 100 U/ml penicillin G, and 100 µg/ml streptomycin in a humidified 37°C incubator. After reaching confluence, cells were seeded onto either 6-cm dishes for immunoblotting or kinase assays or 12- and 24-well plates for measurement by the IL-6, PGE2, cAMP, or {kappa}B luciferase assays.

Measurements of IL-6 and PGE2 production

RAW 264.7 macrophages were cultured in 24-well culture plates. After reaching confluence, cells were treated with various stimulators or pretreated with specific inhibitors as indicated, followed by PGN, and then incubated in a humidified incubator at 37°C for 24 h. After incubation, the medium was removed and stored at –80°C until assay. IL-6 or PGE2 in the medium was assayed using the IL-6 or PGE2 enzyme immunoassay kits, respectively, according to the procedure described by the manufacturer.

Measurement of intracellular cAMP concentration

RAW 264.7 macrophages were cultured in 12-well culture plates. After reaching confluence, cells were treated with PGN (30 µg/ml) for various time intervals, or pretreated with specific inhibitors as indicated followed by PGN, and then incubated in a humidified incubator at 37°C for 6 h. After incubation, the reaction was terminated by aspiration of the medium and the addition of 0.1 N HCl for 20 min. The cells were scraped into Eppendorf tubes, and the suspensions were centrifuged; the supernatants were then neutralized with 10 N NaOH. Samples were stored at –80°C until assay. cAMP levels were assayed using the cAMP enzyme immunoassay kit according to the procedure described by the manufacturer.

Immunoblot analysis

To determine the expressions of IKK{alpha}beta phosphorylation at Ser180/181; IKK{alpha}beta; and p65 phosphorylation at Ser276, p65, iNOS, COX-2, and {alpha}-tubulin in RAW 264.7 macrophages, proteins were extracted, and Western blot analysis was performed as described previously (36). Briefly, RAW 264.7 macrophages were cultured in 6-cm dishes. After reaching confluence, cells were treated with vehicle, PGN, PGE2, and 8-bromo-cAMP or pretreated with specific inhibitors as indicated followed by PGN. After incubation, cells were washed twice in ice-cold PBS and solubilized in extraction buffer containing 10 mM Tris (pH 7.0), 140 mM NaCl, 2 mM PMSF, 5 mM DTT, 0.5% Nonidet P-40, 0.05 mM pepstatin A, and 0.2 mM leupeptin. Samples of equal amounts of protein (100 µg) were subjected to SDS-PAGE and then transferred onto a polyvinylidine difluoride which was then incubated in 150 mM NaCl, 20 mM Tris-HCl, 0.02% Tween 20 (pH 7.4) buffer containing 5% BSA. Proteins were visualized by specific primary Abs and then incubated with HRP- or alkaline phosphatase-conjugated second Abs. Immunoreactivity was detected using ECL or nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate following the manufacturer’s instructions. Quantitative data were obtained using a computing densitometer with scientific imaging systems.

Immunoprecipitation and IKK{alpha}beta activity assay

RAW 264.7 cells were grown in 6-cm dishes. After reaching confluence, cells were treated with 30 µg/ml PGN for the indicated time intervals. After incubation, cells were washed twice with ice-cold PBS; lysed in 1 ml of lysis buffer containing 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 125 mM NaCl, 1% Triton X-100, 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 25 mM beta-glycerophosphate, 50 mM NaF, and 100 µM sodium orthovanadate; and then centrifuged. The supernatant was immunoprecipitated with respective polyclonal Abs against IKK{alpha}beta in the presence of A/G-agarose beads overnight. The beads were washed three times with lysis buffer and twice with kinase buffer containing 20 mM HEPES (pH 7.4), 20 mM MgCl2, 1 mM NaVO4, and 2 mM DTT. The kinase reactions were performed by incubating immunoprecipitated beads with 20 µl of kinase buffer supplemented with 20 µM ATP and 3 µCi of [{gamma}-32P]ATP at 30°C for 30 min. To assess the IKK{alpha}beta activity, 0.5 µg of GST-I{kappa}B{alpha} protein (aa 1–317) was added to the substrate. The reaction mixtures were analyzed by 12% SDS-PAGE followed by autoradiography.

Preparation of nuclear extracts and the EMSA

RAW 264.7 macrophages were cultured in 6-cm dishes. After reaching confluence, cells were treated with 30 µg/ml PGN for indicated time intervals; then cells were scraped and collected. The cytosolic and nuclear protein fractions were separated as described previously (37). Briefly, cells were washed with ice-cold PBS and pelleted. Cell pellets were resuspended in hypotonic buffer (10 mM HEPES (pH 7.9), 10 mM KCl, 0.5 mM DTT, 10 mM aprotinin, 10 mM leupeptin, and 20 mM PMSF) for 15 min on ice, and vortexed for 10 s. Nuclei were pelleted by centrifugation at 15,000 x g for 1 min. Supernatants containing cytosolic proteins were collected. A pellet containing nuclei was resuspended in hypertonic buffer (20 mM HEPES (pH 7.6), 25% glycerol, 1.5 mM MgCl2, 4 mM EDTA, 0.05 mM DTT, 10 mM aprotinin, 10 mM leupeptin, and 20 mM PMSF) for 30 min on ice. Supernatants containing nuclear proteins were collected by centrifugation at 15,000 x g for 30 min and then stored at –70°C.

A double-stranded oligonucleotide probe containing an NF-{kappa}B sequence (5'-AGTTGAGGGGACTTTCCCAGGC-3'; Promega) was purchased and end-labeled with [{gamma}-32P]ATP using T4 polynucleotide kinase. The nuclear extract (2.5–5 µg) was incubated with 1 ng of a 32P-labeled NF-{kappa}B probe (50,000–75,000 cpm) in 10 µl of binding buffer containing 1 µg of poly(deoxyinosinate-deoxycytidylate), 15 mM HEPES (pH 7.6), 80 mM NaCl, 1 mM EDTA, 1 mM DTT, and 10% glycerol at 30°C for 25 min. DNA-nuclear protein complexes were separated from the DNA probe by electrophoresis on 4.5% polyacrylamide gels. Gels were vacuum dried and subjected to autoradiography with an intensifying screen at –80°C. For competition experiments, 1 ng of the labeled oligonucleotide was mixed with 50 ng of unlabeled competitor oligonucleotides before protein addition. For the supershift experiments, 4 µg of anti-p65 or anti-p50 Ab were mixed with the nuclear extract proteins.

Transfection and {kappa}B luciferase assays

For these assays, 2 x 105 RAW 264.7 cells were seeded onto 12-well plates, and cells were transfected the next day using GenePORTER 2 with 0.3 µg of pGL2-ELAM-Luc and 0.3 µg of pBK-CMV-LacZ. After 24 h, the medium was aspirated and replaced with fresh DMEM-Ham’s F-12 containing 10% FBS and was then pretreated with specific inhibitors as indicated followed by PGN (30 µg/ml) treatment for another 24 h. Luciferase activity was determined with a luciferase assay system (Promega), and was normalized on the basis of LacZ expression. The level of induction of luciferase activity was compared as the ratio of cells with and without stimulation.

Measurement of NO concentration

NO production was assayed by measuring nitrite (a stable degradation product of NO) in the supernatant of cultured RAW 264.7 cells using the Griess reagent. Briefly, RAW 264.7 macrophages were cultured in 24-well plates. After reaching confluence, the culture medium was changed to phenol red-free DMEM. Cells were then treated with PGN (30 µg/ml) for the indicated time intervals or pretreated with specific inhibitors as indicated, followed by PGN. After incubation, the supernatant was collected, mixed with an equal volume of Griess reagent (1% sulfanilamide, 0.1% N-(1-naphthyl)ethylenediamine, and 2% phosphoric acid), and incubated at room temperature for 10 min. The OD measured at 550 nm in a microplate reader was used as an indication of the nitrite concentration. Sodium nitrite was used to produce a standard curve of nitrite concentration.

Statistical analysis

Results are presented as the mean ± SE from at least three independent experiments. One-way ANOVA followed by, when appropriate, Bonferroni’s multiple range test was used to determine the statistical significance of the difference between means. p < 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
PGN induces macrophage IL-6 production

Murine RAW 264.7 macrophages were chosen to investigate the signal pathways of PGN in the production of IL-6, an inflammatory response gene. Treatment with PGN (1–100 µg/ml) for 24 h induced IL-6 production in a concentration-dependent manner (Fig. 1A), this induction occurred in a time-dependent manner (Fig. 1B). After 24 h of treatment with 30 µg/ml PGN, the amount of IL-6 released had increased by ~235 ± 64% (Fig. 1B). To further confirm this stimulation-specific mediation by PGN without LPS contamination, polymyxin B, an LPS inhibitor, was tested. We found that polymyxin B (1 µM) completely inhibited LPS (1 µg/ml)-induced IL-6 release. However, it had no effect on PGN (30 µM)-induced IL-6 release (Fig. 1C).


Figure 1
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 1. Concentration- and time-dependent increases in IL-6 production by PGN and effects of polymyxin B on LPS- and PGN-induced IL-6 production in RAW 264.7 macrophages. Cells were incubated with various concentrations of PGN for 24 h (A) or with 30 µg/ml PGN for 2, 4, 6, 8, 12, 18, or 24 h (B). Media were collected to measure IL-6. Results are expressed as the mean ± SE of four independent experiments performed in triplicate. *, p < 0.05 as compared with the basal level. C, Cells were pretreated with polymyxin B (Poly B, 1 µM) for 30 min before incubation with 1 µg/ml LPS or 30 µg/ml PGN for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the LPS or PGN treatment groups, respectively.

 
Involvement of PGE2 formation in PGN-induced IL-6 release

Our previous study showed that PGN can induce COX-2 expression in RAW 264.7 macrophages (35). Next, we further examined PGE2 formation by PGN stimulation in RAW 264.7 macrophages. Treatment of cells with 30 µg/ml PGN for 2, 4, 6, 8, 12, 18, or 24 h induced PGE2 formation in a time-dependent manner. PGE2 formation increased at 2 h and peaked at 12~24 h (Fig. 2A). To examine whether COX-2-generated PGE2 formation is involved in the signal transduction pathway leading to IL-6 production caused by PGN, the nonselective COX inhibitor indomethacin and the selective COX-2 inhibitor NS398 were used. Fig. 2B shows that PGN-induced IL-6 production was inhibited by indomethacin (10 µM) and NS398 (1 µM) by 92 ± 10% and 93 ± 7%, respectively. Furthermore, stimulation of cells with PGE2 (0.001–1 µM) also resulted in IL-6 production in a concentration-dependent manner (Fig. 2C). When cells were treated with 1 µM PGE2 for 24 h, IL-6 production increased by ~480 ± 70% (Fig. 2C). These results suggest that COX-2-generated PGE2 formation is necessary for PGN-induced IL-6 release in RAW 264.7 macrophages.


Figure 2
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 2. Involvement of PGE2 formation in PGN-mediated IL-6 production in RAW 264.7 macrophages. A, Cells were incubated with 30 µg/ml PGN for 2, 4, 6, 8, 12, 18, or 24 h. Media were collected to measure PGE2. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the basal level. B, Cells were pretreated for 30 min with 10 µM indomethacin and 1 µM NS398 and then stimulated with 30 µg/ml PGN for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of four independent experiments performed in triplicate. *, p < 0.05 as compared with the PGN treatment group. C, Cells were incubated with various concentrations of PGE2 for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the basal level.

 
Involvement of EP2 and EP4 receptors in PGN-induced IL-6 production

There are four types of EPs that have been defined and cloned, EP1, EP2, EP3, and EP4 (28). A previous study revealed that RAW 264.7 macrophages express EP2, EP3, and EP4, but not EP1, receptors (38). To identify the EP receptors involved in PGN-mediated IL-6 production, the EP2 receptor antagonist AH6809 and the EP4 receptor antagonist AH23848 were tested. As shown in Fig. 3A, pretreatment of RAW 264.7 macrophages with 3 µM AH6809 and 30 µM AH23848 inhibited PGN-induced IL-6 release by 49 ± 10% and 62 ± 12%, respectively. Treatment of cells with the combination of 3 µM AH6809 and 30 µM AH23848 caused a more arked inhibitory effect on the PGN-induced IL-6 release compared with each agent alone. Furthermore, treatment of RAW 264.7 macrophages with the EP2 agonist butaprost (5 µM) and the EP2/EP3/EP4 agonist misoprostol (100 nM) also resulted in IL-6 release from 75 ± 10 pg/ml to 149 ± 21 and 190 ± 20 pg/ml, respectively, whereas the EP1/EP3 agonist sulprostone (1 µM) had no effect (Fig. 3B). To identify the EP4-mediated effects of misoprostol, RAW 264.7 cells were treated with misoprostol in the presence of the EP2 antagonist AH6809. Treatment of cells with misoprostol in the presence of AH6809 also induced IL-6 production from 75 ± 10 pg/ml to 134 ± 23 pg/ml (Fig. 3B). These results suggest that PGN-induced IL-6 release may occur via activation of EP2 and EP4 receptor signaling.


Figure 3
View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 3. Involvement of EP2 and EP4 receptors in PGN-mediated IL-6 production in RAW 264.7 macrophages. A, Cells were pretreated for 30 min with 3 µM AH6809, 30 µM AH23848, or 3 µM AH6809 + 30 µM AH23848 and then stimulated with 30 µg/ml PGN for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the PGN treatment group. B, Cells were incubated with 1 µM butaprost, 3 µM sulprostone, 1 µM misoprostol, or 1 µM misoprostol + 3 µM AH6089 for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the basal level.

 
Involvement of cAMP formation and PKA activation in PGN-induced IL-6 production

To identify the cAMP-dependent PKA signaling pathways involved in PGN-mediated IL-6 production, RAW 264.7 macrophages were treated with the PKA inhibitor, KT5720. Pretreatment of RAW 264.7 macrophages with KT5720 (0.01~3 µM) inhibited PGN-induced IL-6 production in a concentration-dependent manner (Fig. 4A). When cells were treated with 3 µM KT5720, PGN-induced IL-6 production was inhibited by 82 ± 12% (n = 3). Next, we directly measured cAMP formation in response to PGN. Short term treatment of cells with 30 µg/ml PGN for 5, 10, 30, and 60 min did not cause an increase in cAMP formation (data not shown). However, long term treatment of RAW 264.7 cells with PGN for 2, 4, 6, 8, or 12 h induced cAMP formation in a time-dependent manner. The cAMP formation began at 2 h, peaked at 4–8 h, and then declined at 12 h after PGN treatment (Fig. 4B). We next examined whether PGN-induced cAMP formation occurs through COX-2-generated PGE2 and EP2/EP4 activation. As shown in Fig. 4C, pretreatment of RAW 264.7 macrophages with NS398, AH6809, and AH23848 all inhibited PGN-induced cAMP formation by 90 ± 9%, 61 ± 11%, and 58 ± 15%, respectively.


Figure 4
View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 4. Involvement of cAMP formation and PKA activation in PGN-mediated IL-6 release in RAW 264.7 macrophages. A, Cells were pretreated for 30 min with various concentrations of KT5720 and then stimulated with 30 µg/ml PGN for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the PGN treatment group. B, Cells were incubated with 30 µg/ml PGN for 2, 4, 6, 8, or 12 h. Cell lysates were collected to measure cAMP. Results are expressed as the mean ± SE of four independent experiments performed in triplicate. *, p < 0.05 as compared with the basal level. C, Cells were pretreated for 30 min with 1 µM NS398, 3 µM AH6809, or 30 µM AH23848 and then stimulated with 30 µg/ml PGN for 6 h. Cell lysates were collected to measure cAMP formation. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the PGN treatment.

 
PGE2 and PKA mediated PGN-induced IKK{alpha}beta activation

We further examined whether activation of IKK{alpha}beta occurs through the COX-2-generated PGE2 and PKA signaling pathway. Stimulation of cells with 30 µg/ml PGN for 2, 4, 6, 8, or 12 h induced an increase in IKK{alpha}beta phosphorylation and IKK{alpha}beta activity in time-dependent manners, reaching a maximum after 6–8 h of treatment (Fig. 5). Furthermore, pretreatment of cells for 30 min with NS398 (1 µM) and KT5720 (3 µM) markedly attenuated the PGN-induced IKK{alpha}beta phosphorylation by 62 ± 13% and 86 ± 15%, respectively (Fig. 6A). None of these inhibitors affected the basal IKK{alpha}beta phosphorylation (Fig. 6A). In addition, treatment of RAW 264.7 macrophages with PGE2 (1 µM) caused marked phosphorylation of IKK{alpha}beta, reaching maximums after 10–30 min of treatment (Fig. 6B, lower). Similarly, treatment of cells with the PKA activator, 8-bromo-cAMP (300 µM), also resulted in IKK{alpha}beta phosphorylation in a time-dependent manner, with a maximum effect at 10–30 min of treatment (Fig. 6C). The protein level of IKK{alpha}beta was not affected by PGE2 or 8-bromo-cAMP treatment (Fig. 6, B and C, lower).


Figure 5
View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 5. PGN induced IKK{alpha}beta activation in RAW 264.7 macrophages. A, RAW 264.7 macrophages were treated with 30 µg/ml PGN for 2, 4, 6, 8, or 12 h, and IKK{alpha}beta phosphorylation was shown by immunoblotting with an Ab specific for phosphorylated IKK{alpha}beta (upper panel). Equal loading in each lane is shown by the similar intensities of IKK{alpha}beta (lower panel). Typical traces are representative of three experiments with similar results. B, For evaluation of IKK{alpha}beta activity, cell lysates were incubated with 30 µg/ml PGN for 2, 4, 6, 8, or 12 h, and then lysates were immunoprecipitated with Abs specific for IKK{alpha} and IKKbeta. One set of immunoprecipitates was subjected to the kinase assay (KA) as described in Materials and Methods using the GST-I{kappa}B{alpha} fusion protein as a substrate (top panel). The other set of immunoprecipitates was subjected to 10% SDS-PAGE and analyzed by immunoblotting (IB) with an anti-IKK{alpha}beta Ab (bottom panel). Equal amounts of the immunoprecipitated kinase complex present in each kinase assay were confirmed by immunoblotting for IKK{alpha}beta. Typical traces are representative of three experiments with similar results, which are presented as the mean ± SE. *, p < 0.05 as compared with the basal level.

 

Figure 6
View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 6. Involvement of PGE2 formation and PKA activation in PGN-mediated IKK{alpha}beta phosphorylation in RAW 264.7 macrophages. A, Cells were pretreated with 1 µM NS398 (NS) and 3 µM KT5720 (KT) for 30 min and then treated with 30 µg/ml PGN for 6 h. IKK{alpha}beta phosphorylation was shown by immunoblotting with an Ab specific for phosphorylated IKK{alpha}beta (top panel). Equal loading in each lane is shown by the similar intensities of IKK{alpha}beta (bottom panel). Typical traces are representative of three experiments with similar results, presented as the mean ± SE. *, p < 0.05 as compared with the PGN treatment group. B and C, Cells were treated with 1 µM PGE2 (B) or 300 µM 8-bromo-cAMP (C) for 1, 3, 10, or 30 min, and IKK{alpha}beta phosphorylation was shown by immunoblotting with an Ab specific for phosphorylated IKK{alpha}beta (upper panel). Equal loading in each lane is shown by the similar intensities of IKK{alpha}beta (lower panel). Typical traces are representative of three experiments with similar results.

 
PGE2 and PKA mediated PGN-induced p65 phosphorylation at Ser276

Next, we further examined p65 phosphorylation at Ser276 by PGN stimulation in RAW 264.7 macrophages. Treatment of cells with 30 µg/ml PGN for 2, 4, 6, 8, or 12 h induced p65 phosphorylation at Ser276 in a time-dependent manner (Fig. 7A). The response began at 2 h, was sustained to 4–6 h, and then declined at 8–12 h after PGN treatment (Fig. 7A). We next examined whether PGN-induced p65 phosphorylation at Ser276 occurs through the PGE2 and PKA signaling pathways. As shown in Fig. 7B, pretreatment of cells for 30 min with NS398 (1 µM) and KT5720 (3 µM) markedly attenuated PGN-induced p65 phosphorylation at Ser276 at 53 ± 20% and 79 ± 11%, respectively. Neither of these inhibitors affected the basal p65 protein levels (Fig. 7B, lower).


Figure 7
View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 7. Involvement of PGE2 formation and PKA activation in PGN-mediated p65 Ser276 phosphorylation (-p) in RAW 264.7 macrophages. A, RAW 264.7 macrophages were treated with 30 µg/ml PGN for 2, 4, 6, 8, or 12 h, and p65 phosphorylation at Ser276 was shown by immunoblotting with an Ab specific for phosphorylated p65 at Ser276 (upper panel). Equal loading in each lane is shown by the similar intensities of p65 (lower panel). Typical traces are representative of three experiments with similar results. B, Cells were pretreated with 1 µM NS398 (NS) and 3 µM KT5720 (KT) for 30 min and then treated with 30 µg/ml PGN for another 6 h. p65 phosphorylation at Ser276 was shown by immunoblotting with an Ab specific for phosphorylated p65 at Ser276 (top panel). Equal loading in each lane is shown by the similar intensities of p65 (middle panel). Typical traces are representative of three experiments with similar results, presented as the mean ± SE. *, p < 0.05 as compared with the PGN treatment group.

 
COX-2-generated PGE2, EP2/EP4s, PKA, and IL-6 itself mediated PGN-induced NF-{kappa}B activation

To examine whether COX-2-generated PGE2-induced NF-{kappa}B activation is required for PGN-induced IL-6 production, pretreatment of RAW 264.7 macrophages with the NF-{kappa}B inhibitor, pyrrolidine dithiocarbamate (PDTC, 50 µM), inhibited PGN- and PGE2-induced IL-6 production by 44 ± 5% and 77 ± 14%, respectively (Fig. 8A). Furthermore, the time course of NF-{kappa}B activation after treatment with 30 µg/ml PGN was evaluated by a gel shift DNA binding assay. As shown in Fig. 8B, stimulation of cells with PGN for 10 and 30 min and 1, 2, 4, 6, 8, and 12 h resulted in a two waves of formation of the NF-{kappa}B-specific DNA-protein complex. The first wave of NF-{kappa}B activation occurred at 10–60 min of treatment and the later wave at 2–12 h of treatment. To identify the specific subunits involved in the formation of the NF-{kappa}B complex, supershift assays were performed using Abs specific for anti-p65 and anti-p50. Incubation of nuclear extracts with Abs specific for anti-p65 and anti-p50 attenuated NF-{kappa}B-specific DNA-protein complex formation (Fig. 8C, lanes 3 and 4). These results indicated that the components of the NF-{kappa}B complex are p65 and p50. Formation of the NF-{kappa}B complex was completely inhibited by the 50-fold cold NF-{kappa}B consensus DNA sequence (Fig. 8C, lane 5), indicating that DNA-protein interactions are sequence specific. We further examined whether the COX-2-generated PGE2 and PKA signaling pathway are involved in the PGN-induced activation of NF-{kappa}B in two waves. Pretreatment of cells with 1 µM NS398 or 3 µM KT5720 did not affect the first wave of NF-{kappa}B-specific DNA-protein complex formation caused by short term (30 min) treatment (Fig. 8D), whereas both inhibited the later wave of NF-{kappa}B activation caused by the long term (6 h) treatment of PGN (Fig. 8E). To directly determine NF-{kappa}B activation after PGN treatment, RAW 264.7 macrophages were transiently transfected with pGL2-ELAM-{kappa}B luciferase as an indicator of NF-{kappa}B activation. When cells were treated with 30 µg/ml PGN for 24 h, the {kappa}B luciferase activity increased by ~550 ± 62% (Fig. 9A). Furthermore, we found that pretreatment of cells for 30 min with 10 µM indomethacin, 1 µM NS398, and 3 µM KT5720 markedly attenuated the PGN-induced increase in {kappa}B luciferase activity by 77 ± 15%, 83 ± 14%, and 86 ± 10%, respectively (Fig. 9A). To test the possibility that IL-6 itself induced NF-{kappa}B activation, an anti-IL-6 Ab was used. Pretreatment of RAW 264.7 macrophages with 0.3 ng/ml anti-IL-6 Ab inhibited the PGN-induced later wave of NF-{kappa}B-specific DNA-protein complex formation (Fig. 8E) as well as the increase in {kappa}B luciferase activity (Fig. 9A). Furthermore, treatment of cells with IL-6 (1 and 10 ng/ml) also resulted in an increase in {kappa}B luciferase activity of 169 ± 17% with 10 ng/ml IL-6 treatment (Fig. 9B). Next, we wanted to identify whether EP2 and EP4 are involved in PGN-mediated NF-{kappa}B activation. We found that 3 µM AH6809 and 30 µM AH23848 inhibited the PGN-induced increase in {kappa}B luciferase activity by 51 ± 4% and 50 ± 6%, respectively (Fig. 9C). Furthermore, treatment of AH6809 and AH23848 in combination with RAW 264.7 macrophages resulted in a more marked inhibitory effect on the PGN-induced response compared with each agent alone (Fig. 9C). Taken together, these data suggest that COX-2-generated PGE2, EP2/EP4, PKA, and IL-6 itself are involved in the PGN-induced later wave of NF-{kappa}B activation in RAW 264.7 macrophages.


Figure 8
View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 8. Involvement of COX-2-generated PGE2, PKA activation, and IL-6 formation in PGN-mediated NF-{kappa}B activation in RAW 264.7 macrophages. A, Cells were pretreated for 30 min with 50 µM PDTC and then stimulated with 30 µg/ml PGN or 1 µM PGE2 for 24 h. Media were collected to measure IL-6. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the PGN or PGE2 treatment group, respectively. B, Cells were treated with 30 µg/ml PGN for the indicated time interval. The nuclear extracts were then prepared, and NF-{kappa}B-specific DNA-protein complex formation was determined by EMSA as described in Materials and Methods. Top band, NF-{kappa}B. C, Cells were incubated with 30 µg/ml PGN for 30 min. The nuclear extract was prepared, and EMSA was performed as described above. Top band, NF-{kappa}B. Results of a competition experiment using 50-fold unlabeled NF-{kappa}B oligonucleotide (50x competitor) and a supershift experiment with 4 µg of the anti-p65 or anti-p50 Ab performed on the nuclear extract from PGN treatment are also shown. Typical traces are representative of two experiments with similar results. D and E, Cells were pretreated with 1 µM NS398 (NS), 3 µM KT5720 (KT), or 0.3 ng/ml anti-IL-6 Ab for 30 min and then stimulated with 30 µg/ml PGN for another 30 min (D) or 6 h (E) of treatment, respectively. Nuclear extracts were prepared for determination of NF-{kappa}B-specific DNA-protein complex formation by EMSA as described above. Typical traces are representative of two experiments with similar results.

 

Figure 9
View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 9. Involvement of COX-2-generated PGE2, EP2, and EP4 receptors, IL-6 formation, p38 MAPK, and PKC activation in PGN-mediated NF-{kappa}B activation in RAW 264.7 macrophages. RAW 264.7 macrophages were transiently transfected with 0.3 µg of pGL2-ELAM-Luc and 0.3 µg of pBK-CMV-LacZ for 24 h. Cells were pretreated with 10 µM indomethacin, 1 µM NS398, 3 µM KT5720, 0.3 ng/ml anti-IL-6 Ab (A), 3 µM AH6809, 30 µM AH23848, 3 µM AH6809 + 30 µM AH23848 (C), 1 µM Ro31-8220, or 1 µM SB203580 (D) for 30 min and then stimulated with 30 µg/ml PGN (A, C, and D) or 300 nM 8-bromo-cAMP (D) for another 24 h. Luciferase activities were determined as described in Materials and Methods. The level of induction of luciferase activity was compared with that of cells without PGN (A, C, and D) or 8-bromo-cAMP (D) treatment. Data represent the mean ± SE of three experiments performed in duplicate. *, p < 0.05 as compared with the PGN (A, C, and D) or 8-bromo-cAMP (D) treatment group, respectively. B, RAW 264.7 macrophages were transiently transfected with 0.3 µg of pGL2-ELAM-Luc and 0.3 µg of pBK-CMV-LacZ for 24 h. Cells were stimulated with IL-6 (1–10 ng/ml) for another 24 h. Luciferase activities were determined as described above. The level of induction of luciferase activity was compared with that of cells without IL-6 treatment. Data represent the mean ± SE of three experiments performed in duplicate. *, p < 0.05 as compared with the basal level.

 
PKC and p38 MAPK mediated PGN-induced NF-{kappa}B activation

To identify whether PKA regulates the activity of other signaling molecules that lead to NF-{kappa}B activation caused by PGN, the PKC inhibitor Ro31-8220 and the p38 MAPK inhibitor SB203580 were used. Fig. 9D shows that pretreatment of cells with 1 µM Ro31-8220 and 1 µM SB203580 inhibited the PGN-induced increase in {kappa}B luciferase activity by 66 ± 8% and 45 ± 8%, respectively. Furthermore, 8-bromo-cAMP, a PKA activator, which induced an increase in {kappa}B luciferase activity was also inhibited by both inhibitors by 70 ± 4% and 42 ± 5%, respectively.

NO is not involved in PGN-induced IL-6 release

Treatment with 30 µg/ml PGN for various time intervals induced iNOS expression and nitrite release in a time-dependent manner (Fig. 10, A and B). After 24 h of treatment with 30 µg/ml PGN, the nitrite release had increased by ~539 ± 131% (Fig. 10B). To explore whether NO might mediate PGN-induced IL-6 release, a nonselective inhibitor of NOS, L-NAME, was used. As shown in Fig. 10C, pretreatment of RAW 264.7 macrophages with L-NAME (100 and 300 µM) markedly inhibited the PGN-induced nitrite release by 38 ± 14% and 79 ± 9%, respectively. However, L-NAME (100 and 300 µM) did not affect PGN-induced IL-6 release (Fig. 10D).


Figure 10
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 10. NO is not involved in PGN-mediated IL-6 production in RAW 264.7 macrophages. A, Cells were incubated with 30 µg/ml PGN for the indicated time intervals and then immunodetected using specific Abs against iNOS or {alpha}-tubulin as described in Materials and Methods. Data are representative of three independent experiments that gave essentially identical results. The extents of iNOS and {alpha}-tubulin protein expressions were quantitated using a densitometer with scientific imaging systems. The relative level was calculated as a percentage of the control level. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the control group. Equal loading in each lane is demonstrated by similar intensities of {alpha}-tubulin. B, Cells were incubated with 30 µg/ml PGN for the indicated time intervals. Media were collected to measure nitrite release. Results are expressed as the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05 as compared with the control group. C and D, Cells were pretreated for 30 min with vehicle or L-NAME (100 and 300 µM) and then stimulated with 30 µg/ml PGN for 24 h. Media were collected to measure of nitrite (C) and IL-6 (D), respectively. Results are expressed as the mean ± SE of four independent experiments performed in triplicate. *, p < 0.05 as compared with the PGN treatment group.

 
Positive feedback of COX-2-generated PGE2 in PGN-induced COX-2 expression

We further examined whether PGN-induced COX-2 expression occurs via positive feedback with the COX-2-generated PGE2 signaling pathway. As shown in Fig. 11A, pretreatment of RAW 264.7 macrophages with 1 µM NS398, 10 µM indomethacin, and 1 µM KT5720 inhibited PGN-induced COX-2 expression by 53 ± 10%, 58 ± 13%, and 91 ± 5%, respectively. Furthermore, treatment of RAW 264.7 macrophages with PGE2 (0.01–1 µM) and 8-bromo-cAMP (30–300 µM) also resulted in increases in COX-2 expression in concentration-dependent manners. When cells were treated with 1 µM PGE2 or 300 µM 8-bromo-cAMP for 24 h, COX-2 expression increased by ~241 ± 67% or 1701 ± 243%, respectively (Fig. 11, B and C). These results suggest that PGN-induced COX-2 expression can be regulated partially through positive feedback of COX-2-generated PGE2 and subsequently through cAMP/PKA signaling pathways.


Figure 11
View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 11. Positive feedback of COX-2-generated PGE2 involved in PGN-mediated COX-2 expression in RAW 264.7 macrophages. A, Cells were pretreated with 1 µM NS398 (NS), 10 µM indomethacin (Indo), and 3 µM KT5720 (KT) for 30 min followed by stimulation with 30 µg/ml PGN for another 24 h, and COX-2 expression was determined by immunoblotting with an Ab specific for COX-2. Equal loading in each lane is demonstrated by the similar intensities of {alpha}-tubulin. Typical traces are representative of three experiments with similar results, which are presented as the mean ± SE. *, p < 0.05 as compared with PGN treatment. In B and C, cells were incubated with PGE2 (0.01–1 µM) (B) or 8-bromo-cAMP (30–300 µM) (C) for 24 h, and then COX-2 or {alpha}-tubulin protein levels were determined. Equal loading in each lane is shown by the similar intensities of {alpha}-tubulin. Traces represent results from three independent experiments, presented as the mean ± SE. *, p < 0.05 as compared with the control group.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this study, we show that PGN induces IL-6 production in RAW 264.7 macrophages by a mechanism involving COX-2 induction, PGE2 release, and PKA activation. Several lines of evidence suggest that PGE2 may play a vital role in IL-6 production (30, 31, 32, 33, 34). It has been shown that exogenous PGE2 can stimulate IL-6 production in macrophages and astrocytes (31, 39, 40). Furthermore, it is well established that eicosanoid-producing enzymes, such as COX-2, are expressed in RAW 264.7 macrophages and are regulated by many factors, including cytokines and infectious agents (35, 41, 42). Furthermore, COX-2 is thought to contribute to the generation of PGs at sites of inflammation (27). Because PGN has been shown to stimulate COX-2 protein expression after 2 h of treatment (35), we hypothesized that COX-2 products may be involved in mediating the PGN-induced increase in IL-6 production. Our study has revealed that PGN induced PGE2 formation in a time-dependent manner. The respective increases after 2, 4, 6, 8, 12, 18, and 24 h of treatment were 3-, 7-, 9-, 16-, 23-, 26-, and 24-fold of the basal level, paralleling the increase in COX-2 expression stimulated by PGN (35). We also found that PGE2 added to the culture medium increases IL-6 production and that the nonselective COX inhibitor indomethacin and the selective COX-2 inhibitor NS398 blocked PGN-induced IL-6 production. These results indicate that COX-2-generated PGE2 plays a critical role in PGN-stimulated IL-6 production. Furthermore, we found that PGN induces iNOS expression and nitrite release and that the nonselective NOS inhibitor, L-NAME, did not inhibit PGN-induced IL-6 production, suggesting that iNOS expression and NO formation are not involved in the signaling pathway of PGN-induced IL-6 production. These findings support those from another study on LPS (32), a cell wall component of Gram-negative bacteria, in J774.2 macrophages. We also found that treatment of RAW 264.7 cells with PGE2 and the PKA activator 8-bromo-cAMP resulted in increases in COX-2 expression and that indomethacin, NS398, and the PKA inhibitor KT5720 blocked PGN-induced COX-2 expression. These results suggest that PGN-induced COX-2 expression may be partially regulated through positive feedback of COX-2-generated PGE2 and subsequently through cAMP/PKA signaling pathways.

The action of PGE2 occurs via four different transmembrane receptors, namely EP1, EP2, EP3, and EP4 (28). Previous studies demonstrated that RAW 264.7 macrophages express EP2, EP3, and EP4, but not EP1, receptors (38). We found that the EP2 antagonist AH6809 and the EP4 antagonist AH23848 markedly inhibited PGN-induced IL-6 production. The combination of AH6809 and AH23848 showed a more marked inhibitory effect. Although AH23848 is also a thromboxane A2 receptor (TP) antagonist, RAW 264.7 macrophages do not express the TP (38). Therefore, we ruled out the possibility that the inhibitory effect of AH23848 on PGN-induced IL-6 release occurs via the TP. Previous studies have indicated that sulprostone, butaprost, and misoprostol are agonists for EP1/EP3, EP2, and EP2/EP3/EP4, respectively (43, 44). In this study, we found that butaprost, misoprostol, and misoprostol in the presence of the EP2 antagonist AH6809 resulted in IL-6 release, whereas sulprostone did not. These results suggest that PGN-stimulated IL-6 production is mediated via the EP2 and EP4 receptors. EP2 and EP4 are G-protein-coupled receptors that activate adenylyl cyclase upon ligand binding and result in increased cAMP levels and activation of PKA (29). In this study, we found that PGN induced cAMP formation and that NS398, AH6809, and AH23848 inhibited PGN-induced cAMP formation. Furthermore, the specific PKA inhibitor suppressed PGN-induced IL-6 production. The increase in cAMP formation was approximately parallel to the levels of endogenously produced PGE2 stimulated by PGN. These results suggest that COX-2-generated PGE2 acts as an autocrine/paracrine factor for stimulating PGN-induced IL-6 production via the EP2/EP4 receptor-mediated cAMP/PKA signaling pathways. This suggestion is further supported by previous reports that LPS induces an increase in cAMP levels through PGE2 formation in peritoneal macrophages and RAW 264.7 macrophages (45, 46). A previous report also indicated that in cultured Caco-2 cells, the cAMP-dependent PKA signaling pathway is involved in IL-1beta-induced IL-6 production (47).

In mice and humans, the IL-6 promoter has many transcription factors including NF-{kappa}B in the 5' region of the IL-6 gene (11, 12). Several studies have demonstrated that NF-{kappa}B plays a vital role in mediating the up-regulation of IL-6 protein induced by several inflammatory mediators (48, 49). We found that the NF-{kappa}B inhibitor PDTC inhibited PGN- and PGE2-induced IL-6 production, suggesting that PGE2-dependent NF-{kappa}B activation is required for PGN-induced IL-6 production. Short term (5–60 min) treatment of cells with PGN did not cause an increase in cAMP formation, whereas long term (2–12 h) treatment of cells induced cAMP formation, with a maximum effect at 4–8 h after PGN treatment. Furthermore, stimulation of cells with PGN resulted in a two waves of formation of the NF-{kappa}B-specific DNA-protein complex. The first wave of NF-{kappa}B activation occurred at 10–60 min of treatment, whereas the later wave occurred at 2–12 h of treatment. We also found that a specific COX-2 inhibitor and a PKA inhibitor inhibited the PGN-induced later wave of NF-{kappa}B-specific DNA-protein complex formation, but not the first wave of NF-{kappa}B activation. These results suggest that PGN-induced IL-6 production requires two separate activation steps for NF-{kappa}B: the first wave of NF-{kappa}B activation may be PGE2/cAMP-independent; whereas the later wave of NF-{kappa}B activation may be PGE2/cAMP dependent.

It has been shown that the cAMP/PKA pathway is involved in LPS-induced NF-{kappa}B activation in RAW 264.7 macrophages (46). PKA was found to mediate NF-{kappa}B activation through the IKK{alpha}beta complex in J774.2 macrophages (50). In the present study, we found that the PGN-mediated increase in IKK{alpha}beta activity is a delayed event. The respective increases after 2, 4, 6, and 8 h of treatment were 0.5-, 0.6-, 2.5-, and 2.1-fold of the basal level, with the maximum effect at 6–8 h treatment, paralleling the increase in cAMP formation. The later wave activation of DNA-protein complex formation caused by PGN showed an increase after 2 h of treatment and a maximal level at 8–12 h of treatment; this occurred downstream of IKK{alpha}beta activation. We also found that a specific COX-2 inhibitor and a PKA inhibitor inhibit the PGN-induced increase in IKK{alpha}beta activation and {kappa}B luciferase activity. Furthermore, exogenous PGE2 and the direct PKA activator 8-bromo-cAMP also cause IKK{alpha}beta activation or an increase in {kappa}B luciferase activity. These results indicate that IKK{alpha}beta-dependent NF-{kappa}B activation occurs downstream of the signaling pathway of COX-2-generated PGE2 and PKA activation stimulated by PGN. Moreover, we also showed that the EP2 antagonist, AH6809, and the EP4 receptor antagonist, AH23848, inhibited the PGN-induced increase in {kappa}B luciferase activity. The combination of AH6809 and AH23848 resulted in a more marked inhibitory effect in the PGN-induced increase in {kappa}B luciferase activity. These results suggest that COX-2-generated PGE2 induced by PGN occurs via EP2 and EP4 receptor activation by mediating NF-{kappa}B activation. Previous studies have also shown that IL-6 induces NF-{kappa}B activation in intestinal epithelial cells (51). Therefore, it is possible that IL-6 production is involved in PGN-induced NF-{kappa}B activation. In the present study, we found that IL-6 caused an increase in {kappa}B luciferase activity and that the anti-IL-6 Ab inhibited the PGN-induced later wave of NF-{kappa}B-specific DNA-protein complex formation and an increase in {kappa}B luciferase activity. These results suggest that IL-6 production also acts as an autocrine/paracrine factor for PGN-induced NF-{kappa}B activation. In this study, we also found that a PKC inhibitor (Ro31-8220) and a p38 MAPK inhibitor (SB203580) inhibited the PGN- and 8-bromo-cAMP-induced increase in {kappa}B luciferase activity, suggesting that PKA regulates the activities of PKC and p38 MAPK that leads to NF-{kappa}B activation caused by PGN. This suggestion is further supported by a previous report that PKA induces NF-{kappa}B activation via the PKC and p38 MAPK signaling pathway in J774.2 macrophages (50).

Recent studies have suggested that PKA may be involved in events leading to enhanced phosphorylation of the p65 subunit of NF-{kappa}B and the subsequent enhanced transactivation potential of NF-{kappa}B once it is bound to its consensus sequence (21, 52). In this study, we found that PGN causes p65 phosphorylation at Ser276 in a time-dependent manner. The maximum occurred after 6 h of treatment, and this effect was parallel to cAMP formation, IKK{alpha}beta activation, and NF-{kappa}B activation. Furthermore, a specific COX-2 inhibitor (NS398) and a PKA inhibitor (KT5720) inhibited PGN-stimulated p65 phosphorylation at Ser276. These results suggest that p65 phosphorylation also occurs downstream of COX-2-generated PGE2 and PKA activation in the PGN-mediated signaling pathway.

In conclusion, the findings of our study for the first time show that PGN-induced IL-6 production involves COX-2-generated PGE2, EP2, and EP4 receptor activation; intracellular cAMP formation; and the activations of PKA, PKC, p38 MAPK, IKK{alpha}beta, p65 phosphorylation, and NF-{kappa}B. PGN-induced COX-2 expression may be partially regulated through positive feedback by COX-2-generated PGE2 formation. However, PGN-induced iNOS expression and nitrite release were not involved in the signaling pathway of PGN-induced IL-6 production. Fig. 12 is a schematic representation of the signaling pathway of PGN-induced IL-6 production in RAW 264.7 macrophages. By understanding these signal transduction pathways, we can design therapeutic strategies to reduce inflammation caused by Gram-positive organisms.


Figure 12
View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 12. Schematic summary of signal transduction by PGN induction of macrophage IL-6 production in RAW 264.7 macrophages. PGN might activate the Ras/Raf-1/ERK pathway through recruitment of Ras and p85{alpha} to TLR2 to mediate an increase in IKK{alpha}beta activity and p50/p65 (NF-{kappa}B) activation, which lead to COX-2 expression and PGE2 release. PGN-induced PGE2 release result in activation of the EP2 and EP4 receptors and the cAMP/PKA pathway, which in turn increase IKK{alpha}beta activity, p65 phosphorylation at Ser276, and NF-{kappa}B activation, and finally induce IL-6 production in RAW 264.7 macrophages. However, PGN-induced NO release is not involved in the signaling pathway of PGN-induced IL-6 production.

 

   Acknowledgments
 
We thank Dr. Wan-Wan Lin for the gifts of the pGL2-ELAM-Luc and pBK-CMV-LacZ plasmids.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grant NSC 93-2314-B-038-014 from the National Science Council of Taiwan. Back

2 Address correspondence and reprint requests to Dr. Chien-Huang Lin, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan. E-mail address: chlin{at}tmu.edu.tw Back

3 Abbreviations used in this paper: PGN, peptidoglycan; COX-2, cyclooxygenase 2; EP, PGE2 receptor; IKK{alpha}beta, I{kappa}B kinase {alpha}beta; iNOS, inducible nitric oxide synthase; L-NAME, NG-nitro-L-arginine methyl ester; PDTC, pyrrolidine dithiocarbamate; PKA, protein kinase A; PKC, protein kinase C; TP, thromboxane A2 receptor. Back

Received for publication May 19, 2005. Accepted for publication April 14, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Medzhitov, R., C. A. Janeway, Jr. 1998. An ancient system of host defense. Curr. Opin. Immunol. 10: 12-15. [Medline]
  2. Hoffmann, J. A., F. C. Kafatos, C. A. Janeway, R. A. Ezekowitz. 1999. Phylogenetic perspectives in innate immunity. Science 284: 1313-1318. [Abstract/Free Full Text]
  3. Dziarski, R., A. J. Ulmer, D. Gupta. 2000. Interactions of CD14 with components of Gram-positive bacteria. Chem. Immunol. 74: 83-107. [Medline]
  4. Bone, R. C.. 1994. Gram-positive organisms and sepsis. Arch. Intern. Med. 154: 26-34. [Abstract/Free Full Text]
  5. Ulevitch, R. J., P. S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13: 437-457. [Medline]
  6. Graeve, L., M. Baumann, P. C. Heinrich. 1993. Interleukin-6 in autoimmune disease: role of IL-6 in physiology and pathology of the immune defense. Clin. Invest. 71: 664-671. [Medline]
  7. Grimble, R. F.. 1998. Nutritional modulation of cytokine biology. Nutrition 14: 634-640. [Medline]
  8. Jones, S. A.. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175: 3463-3468. [Abstract/Free Full Text]
  9. Yokota, K., T. Miyazaki, M. Hirano, Y. Akiyama, T. Mimura. 2006. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-{alpha} in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 33: 463-471. [Abstract/Free Full Text]
  10. Hirano, T.. 1992. Interleukin-6 and its relation to inflammation and disease. Clin. Immunol. Immunopathol. 62: S60-S65. [Medline]
  11. Grassl, C., B. Luckow, D. Schlondorff, U. Dendorfer. 1999. Transcriptional regulation of the interleukin-6 gene in mesangial cells. J. Am. Soc. Nephrol. 10: 1466-1477. [Abstract/Free Full Text]
  12. Matsusaka, T., K. Fujikawa, Y. Nishio, N. Mukaida, K. Matsushima, T. Kishimoto, S. Akira. 1993. Transcription factors NF-IL6 and NF-{kappa}B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. USA 90: 10193-10197. [Abstract/Free Full Text]
  13. Baldwin, A. S., Jr. 1996. The NF-{kappa}B and I{kappa}B proteins: new discoveries and insights. Annu. Rev. Immunol. 14: 649-683. [Medline]
  14. Thompson, J. E., R. J. Phillips, H. Erdjument-Bromage, P. Tempst, S. Ghosh. 1995. I{kappa}B-beta regulates the persistent response in a biphasic activation of NF-{kappa}B. Cell 80: 573-582. [Medline]
  15. DiDonato, J. A., M. Hayakawa, D. M. Rothwarf, E. Zandi, M. Karin. 1997. A cytokine-responsive I{kappa}B kinase that activates the transcription factor NF-{kappa}B. Nature 388: 548-554. [Medline]
  16. Maniatis, T.. 1997. Catalysis by a multiprotein I{kappa}B kinase complex. Science 278: 818-819. [Free Full Text]
  17. Woronicz, J. D., X. Gao, Z. Cao, M. Rothe, D. V. Goeddel. 1997. I{kappa}B kinase-beta: NF-{kappa}B activation and complex formation with I{kappa}B kinase-{alpha} and NIK. Science 278: 866-869. [Abstract/Free Full Text]
  18. Chen, Z., J. Hagler, V. J. Palombella, F. Melandri, D. Scherer, D. Ballard, T. Maniatis. 1995. Signal-induced site-specific phosphorylation targets I{kappa}B{alpha} to the ubiquitin-proteasome pathway. Genes Dev. 9: 1586-1597. [Abstract/Free Full Text]
  19. Vanden Berghe, W., S. Plaisance, E. Boone, K. De Bosscher, M. L. Schmitz, W. Fiers, G. Haegeman. 1998. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-{kappa}B p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273: 3285-3290. [Abstract/Free Full Text]
  20. Bergmann, M., L. Hart, M. Lindsay, P. J. Barnes, R. Newton. 1998. I{kappa}B{alpha} degradation and nuclear factor-{kappa}B DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-{alpha}-induced {kappa}B-dependent transcription: requirement for an additional activation pathway. J. Biol. Chem. 273: 6607-6610. [Abstract/Free Full Text]
  21. Zhong, H., R. E. Voll, S. Ghosh. 1998. Phosphorylation of NF-{kappa}B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1: 661-671. [Medline]
  22. Wang, D., A. S. Baldwin, Jr. 1998. Activation of nuclear factor-{kappa}B-dependent transcription by tumor necrosis factor-{alpha} is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273: 29411-29416. [Abstract/Free Full Text]
  23. Perkins, N. D., L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, G. J. Nabel. 1997. Regulation of NF-{kappa}B by cyclin-dependent kinases associated with the p300 coactivator. Science 275: 523-527. [Abstract/Free Full Text]
  24. Smith, W. L., D. L. DeWitt, R. M. Garavito. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69: 145-182. [Medline]
  25. Murakami, M., R. Matsumoto, K. F. Austen, J. P. Arm. 1994. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J. Biol. Chem. 269: 22269-22275. [Abstract/Free Full Text]
  26. DeWitt, D., W. L. Smith. 1995. Yes, but do they still get headaches?. Cell 83: 345-348. [Medline]
  27. Otto, J. C., W. L. Smith. 1995. Prostaglandin endoperoxide synthases-1 and -2. J. Lipid Mediat. Cell. Signal. 12: 139-156. [Medline]
  28. Narumiya, S., G. A. FitzGerald. 2001. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108: 25-30. [Medline]
  29. Bos, C. L., D. J. Richel, T. Ritsema, M. P. Peppelenbosch, H. H. Versteeg. 2004. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36: 1187-1205. [Medline]
  30. Ogle, C. K., X. Guo, K. Szczur, S. Hartmann, J. D. Ogle. 1994. Production of tumor necrosis factor, interleukin-6 and prostaglandin E2 by LPS-stimulated rat bone marrow macrophages after thermal injury: effect of indomethacin. Inflammation 18: 175-185. [Medline]
  31. Hinson, R. M., J. A. Williams, E. Shacter. 1996. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 93: 4885-4890. [Abstract/Free Full Text]
  32. Chen, B. C., W. W. Lin. 1999. Potentiation of lipopolysaccharide-induced IL-6 release by uridine triphosphate in macrophages: cross-interaction with cyclooxygenase-2-dependent prostaglandin E2 production. J. Biomed. Sci. 6: 425-432. [Medline]
  33. Spangelo, B. L., P. C. Isakson, R. M. MacLeod. 1990. Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3',5'-monophosphate and vasoactive intestinal peptide. Endocrinology 127: 403-409. [Abstract/Free Full Text]
  34. Anderson, G. D., S. D. Hauser, K. L. McGarity, M. E. Bremer, P. C. Isakson, S. A. Gregory. 1996. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97: 2672-2679. [Medline]
  35. Chen, B. C., Y. S. Chang, J. C. Kang, M. J. Hsu, J. R. Sheu, T. L. Chen, C. M. Teng, C. H. Lin. 2004. Peptidoglycan induces nuclear factor-{kappa}B activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 264.7 macrophages. J. Biol. Chem. 279: 20889-20897. [Abstract/Free Full Text]
  36. Lin, C. H., I. H. Kuan, H. M. Lee, W. S. Lee, J. R. Sheu, Y. S. Ho, C. H. Wang, H. P. Kuo. 2001. Induction of cyclooxygenase-2 protein by lipoteichoic acid from Staphylococcus aureus in human pulmonary epithelial cells: involvement of a nuclear factor-{kappa}B-dependent pathway. Br. J. Pharmacol. 134: 543-552. [Medline]
  37. Chen, C. C., J. K. Wang, W. C. Chen, S. B. Lin. 1998. Protein kinase C{eta} mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes. J. Biol. Chem. 273: 19424-19430. [Abstract/Free Full Text]
  38. Arakawa, T., O. Laneuville, C. A. Miller, K. M. Lakkides, B. A. Wingerd, D. L. DeWitt, W. L. Smith. 1996. Prostanoid receptors of murine NIH 3T3 and RAW 264.7 cells: structure and expression of the murine prostaglandin EP4 receptor gene. J. Biol. Chem. 271: 29569-29575. [Abstract/Free Full Text]
  39. Martin, C. A., M. E. Dorf. 1990. Interleukin-6 production by murine macrophage cell lines P388D1 and J774A. 1. Stimulation requirements and kinetics. Cell. Immunol. 128: 555-568. [Medline]
  40. Fiebich, B. L., S. Schleicher, O. Spleiss, M. Czygan, M. Hull. 2001. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem. 79: 950-958. [Medline]
  41. Chiang, L. L., C. T. Kuo, C. H. Wang, T. F. Chen, Y. S. Ho, H. P. Kuo, C. H. Lin. 2003. Involvement of nuclear factor-{kappa}B in lipoteichoic acid-inducedcyclooxygenase-2 expression in RAW 264.7 macrophages. J. Pharm. Pharmacol. 55: 115-123. [Medline]
  42. Huang, Z. F., J. B. Massey, D. P. Via. 2000. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1beta (IL-1beta) and tumor necrosis factor-{alpha} (TNF-{alpha}) in human in vitro differentiated macrophages. Biochem. Pharmacol. 59: 187-194. [Medline]
  43. Hata, A. N., R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166. [Medline]
  44. Zeng, L., S. An, E. J. Goetzl. 1998. EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells. J. Pharmacol. Exp. Ther. 286: 1420-1426. [Abstract/Free Full Text]
  45. Raddassi, K., J. F. Petit, G. Lemaire. 1993. LPS-induced activation of primed murine peritoneal macrophages is modulated by prostaglandins and cyclic nucleotides. Cell Immunol. 149: 50-64. [Medline]
  46. Chen, C. C., K. T. Chiu, Y. T. Sun, W. C. Chen. 1999. Role of the cyclic AMP-protein kinase A pathway in lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of cyclooxygenase-2. J. Biol. Chem. 274: 31559-31564. [Abstract/Free Full Text]
  47. Hershko, D. D., B. W. Robb, G. Luo, P. O. Hasselgren. 2002. Multiple transcription factors regulating the IL-6 gene are activated by cAMP in cultured Caco-2 cells. Am. J. Physiol. 283: R1140-R1148.
  48. Skurk, T., V. van Harmelen, H. Hauner. 2004. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-{kappa}B. Arterioscler. Thromb. Vasc. Biol. 24: 1199-1203. [Abstract/Free Full Text]
  49. Fan, Z., B. Bau, H. Yang, T. Aigner. 2004. IL-1beta induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NF{kappa}B signaling pathways. Cytokine 28: 17-24. [Medline]
  50. Chio, C. C., Y. H. Chang, Y. W. Hsu, K. H. Chi, W. W. Lin. 2004. PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. Cell. Signal. 16: 565-575. [Medline]
  51. Wang, L., B. Walia, J. Evans, A. T. Gewirtz, D. Merlin, S. V. Sitaraman. 2003. IL-6 induces NF-{kappa}B activation in the intestinal epithelia. J. Immunol. 171: 3194-3201. [Abstract/Free Full Text]
  52. Bird, T. A., K. Schooley, S. K. Dower, H. Hagen, G. D. Virca. 1997. Activation of nuclear transcription factor NF-{kappa}B by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit. J. Biol. Chem. 272: 32606-32612. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B.-C. Chen, H.-M. Chang, M.-J. Hsu, C.-M. Shih, Y.-H. Chiu, W.-T. Chiu, and C.-H. Lin
Peptidoglycan Induces Cyclooxygenase-2 Expression in Macrophages by Activating the Neutral Sphingomyelinase-Ceramide Pathway
J. Biol. Chem., July 31, 2009; 284(31): 20562 - 20573.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Noor, H. Goldfine, D. E. Tucker, S. Suram, L. L. Lenz, S. Akira, S. Uematsu, M. Girotti, J. V. Bonventre, K. Breuel, et al.
Activation of Cytosolic Phospholipase A2{alpha} in Resident Peritoneal Macrophages by Listeria monocytogenes Involves Listeriolysin O and TLR2
J. Biol. Chem., February 22, 2008; 283(8): 4744 - 4755.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. H. Serezani, J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden
Prostaglandin E2 Suppresses Bacterial Killing in Alveolar Macrophages by Inhibiting NADPH Oxidase
Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 562 - 570.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C.-H. Tang, Y.-C. Chiu, T.-W. Tan, R.-S. Yang, and W.-M. Fu
Adiponectin Enhances IL-6 Production in Human Synovial Fibroblast via an AdipoR1 Receptor, AMPK, p38, and NF-{kappa}B Pathway
J. Immunol., October 15, 2007; 179(8): 5483 - 5492.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
S.-i. Tanabe, C. Bodet, and D. Grenier
Peptostreptococcus micros cell wall elicits a pro-inflammatory response in human macrophages
Innate Immunity, August 1, 2007; 13(4): 219 - 226.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
C.-H. Tang, D.-Y. Lu, R.-S. Yang, H.-Y. Tsai, M.-C. Kao, W.-M. Fu, and Y.-F. Chen
Leptin-Induced IL-6 Production Is Mediated by Leptin Receptor, Insulin Receptor Substrate-1, Phosphatidylinositol 3-Kinase, Akt, NF-{kappa}B, and p300 Pathway in Microglia
J. Immunol., July 15, 2007; 179(2): 1292 - 1302.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, B.-C.
Right arrow Articles by Lin, C.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, B.-C.
Right arrow Articles by Lin, C.-H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS